Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetic Study of HDM1005 in Participants With Impaired Renal Function and Healthy Participants
NCT07559240Phase 1Not yet recruiting
- Sponsor
- Huadong Medicine
- Start
- May 2026
- Primary completion
- Jun 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, open-label trial of poterepatide in obesity (3 arms), sponsored by Huadong Medicine. Primary endpoints: Maximum Concentration and Area Under the Concentration Time Curve From Time Zero to t. Planned start May 2026; status: not yet recruiting.
02
Drugs
poterepatide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07559240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07559240.